Retatrutide dosing: how it was given in trials

The dosing information on this page describes how retatrutide was administered in clinical trials. It is informational, not medical advice. Retatrutide is investigational and is not available outside of registered clinical trials.

Higher GLP-1-class doses produce more nausea, particularly when dose increases are stacked too quickly. Slow titration lets the body adjust between steps, which translates directly into fewer participants discontinuing because of GI side effects.

The four-week-per-step Phase 2 schedule kept discontinuation for adverse events around 6–16% across active arms. A faster escalation would likely have produced higher dropout rates, especially at 12 mg. [1]

Phase 3 protocols on ClinicalTrials.gov indicate that the TRIUMPH studies are testing multiple maintenance dose levels — typically including 4 mg, 8 mg, and 12 mg arms — alongside placebo. Lilly will use the safety and efficacy results to determine the commercial label doses, which may or may not include all of the tested levels.

Final dose recommendations cannot be inferred from Phase 2 alone. Smaller doses that produce nearly the same weight loss with better tolerability often become the preferred starting point in commercial labels.

• Semaglutide (Wegovy) — 0.25 mg → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg, with monthly steps.
• Tirzepatide (Zepbound) — 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg, with four-week steps to allowed maintenance doses of 5, 10, or 15 mg.
• Retatrutide (Phase 2) — 2 mg → 4 mg → up to 12 mg, with four-week steps. Maintenance doses studied: 1, 4, 8, 12 mg.

The dose numbersare not directly comparable across molecules because the molecules differ. Each drug's mg count reflects its specific receptor potency profile, not molecular mass.

In trials, retatrutide was administered via a prefilled syringe or pen-style autoinjector into the abdomen, thigh, or upper arm. Participants generally self-administered after training, the same way patients use semaglutide and tirzepatide.

The commercial format — prefilled pen, multi-dose pen, vial, or all of the above — has not been announced. Lilly's recent launches (Mounjaro, Zepbound) shipped both prefilled pens and vials.

Like other once-weekly GLP-1 drugs, retatrutide's long half-life means a missed dose by a day or two has minimal practical consequence. Standard practice for the class is to take the missed dose if it is within a defined window (often ~3 days for tirzepatide), or skip it and resume on the next scheduled day if outside that window. Specific commercial-label guidance will only become official at approval.